Novartis Tried to Outsmart Tumors Through NKG2D. The Tumors Won.

A Pattern, Not a Fluke

If QEQ278 were the only NKG2D program to crash, you might chalk it up to bad luck or imperfect drug design. But it's not alone. Nkarta and Astellas both tried targeting the NKG2D pathway in solid tumors and hit the same wall. Astellas terminated an early CAR-T candidate using NKG2D in January 2025.

This is starting to look less like individual failures and more like the pathway itself is a dead end for solid tumors. It's the biotech equivalent of three different people trying to open the same door and all finding it locked.

The scientific challenges are real and stacking up. Tumors don't just shed their NKG2D ligands; they also create an immunosuppressive microenvironment that exhausts any immune cells that do manage to show up. It's like trying to fight a battle in quicksand. Your soldiers arrive tired, outnumbered, and sinking.

On top of that, NKG2D ligands aren't exclusive to tumors. They also appear on healthy intestinal cells, raising toxicity concerns for any therapy that gets aggressive enough to actually work.

Novartis Isn't Just Trimming — It's Reshuffling the Deck

QEQ278 wasn't the only program Novartis sent to the chopping block. The company cut six Phase 1 oncology programs total, including candidates for prostate cancer, lung cancer, blood cancers, and other solid tumors. The full list of casualties: AAA802, MGY825, KFA115, HRO761, DFV890, and PIT565.

But this isn't a retreat from oncology. Novartis simultaneously added two new Phase 1 programs: AMO959, a DNA repair inhibitor for prostate cancer, and GCJ904, a solid tumor candidate with an undisclosed mechanism. The overall clinical pipeline holds steady at roughly 99 projects.

The message from Novartis is clear: kill what isn't working fast and redeploy the resources. CEO Vas Narasimhan has emphasized pursuing the "highest value medicines," and the company is projecting 5–6% sales growth through 2030 with over 30 potential high-value pipeline assets.

So Is NKG2D Dead?

Not entirely, but the big pharma crowd has largely left the building. The programs still active are mostly run by smaller biotechs and academic centers, think scrappy underdogs rather than pharmaceutical giants.

Several Phase 1 trials are still running. There's a CAR-NK/CAR-T combination study targeting liver metastases in colorectal cancer patients. There's a pediatric sarcoma trial using allogeneic memory NKG2D-CAR T cells. A few others are testing multi-targeted constructs that combine NKG2D with other receptors, hoping that hitting tumors from multiple angles will succeed where single-target approaches have flopped.

These next-generation approaches are incorporating tricks to overcome the known obstacles: better co-stimulatory domains for T-cell persistence, chemokine receptors to improve immune cell trafficking into tumors, and armored CAR designs that resist the immunosuppressive microenvironment.

Will any of them crack the code? Maybe. But the graveyard of NKG2D programs suggests that solid tumors have figured out how to neutralize this line of attack with ruthless efficiency.

The Uncomfortable Truth About Phase 1 Oncology

Phase 1 trials fail all the time; that's literally what early-stage drug development looks like. But zero responses in 30 patients is a particularly brutal outcome. It's not "the drug showed modest activity but not enough." It's "the drug showed nothing."

Novartis deserves credit for cutting cleanly rather than running a larger trial hoping the numbers would somehow improve. In pharma, the most expensive mistake isn't a failed Phase 1. It's a failed Phase 1 you refuse to accept, pouring hundreds of millions into Phase 2 and Phase 3 trials chasing a signal that was never there.

The NKG2D story is a reminder that elegant biology doesn't guarantee good medicine. Sometimes the human body, and the tumors inside it, are just better at the game than we are. At least for now.

Roche's New Breast Cancer Pill Has a Secret Weapon

Roche's oral breast cancer drug giredestrant just got its FDA date, and its secret weapon isn't the drug itself. It's the combination strategy that cut disease progression by 62% in the patients who need it most.